There is a wealth of data surrounding the unique functional and molecular makeup of the sinus node in smaller mammals; however, in humans, there are few data available, with almost no information on the ion channels responsible for pacemaking. This is the first study to investigate the expression of ion channels, Ca 2ϩ -handling proteins, connexins, and receptors in the human sinus node, its surrounding atrial muscle, and a novel area (the paranodal area) that runs alongside the sinus node. This study greatly aids our understanding of the molecular and functional makeup of the human sinus node. For example, in patients, naturally occurring mutations in Na v 1.5 and HCN4 have been linked with familial sick sinus syndrome, and the present study explains why this is so. For treatment of sick sinus syndrome, there has been much interest in the creation of a biological pacemaker, or biopacemaker. Recent strategies have included knocking down K ir 2.1 or overexpressing an HCN (hyperpolarization-activated cyclic nucleotide-gated) channel in the ventricular myocardium; however, the present study results show that there are many differences in gene expression between the human sinus node and working myocardium, which suggests that for a successful and robust biopacemaker to be developed, it is likely that the manipulation of more than 1 gene will be required. In addition, if we understand gene expression, why create a de novo pacemaker in an alien environment? Why not repair the sick sinus by use of gene therapy of the ion channels? See p 1562.
Funny Current Downregulation and Sinus Node Dysfunction Associated With Atrial Tachyarrhythmia: A Molecular Basis for Tachycardia-Bradycardia Syndrome
Sinoatrial node dysfunction is frequently associated with atrial tachyarrhythmias, and patients with the combination are said to suffer from the relatively common tachycardia-bradycardia syndrome. Abnormalities in sinus node pacemaker function on termination of atrial tachyarrhythmias such as atrial fibrillation can cause syncope and require pacemaker implantation, but the underlying mechanisms remain poorly understood. There is evidence from clinical and experimental studies that suggests that a significant component of sinus node dysfunction in patients with the tachycardia-bradycardia syndrome may actually be caused by supraventricular tachyarrhythmia and may be reversible if the tachyarrhythmia is controlled. The present study examined the hypothesis that very rapid atrial tachyarrhythmias can cause ion channel downregulation in the sinus node, thereby causing abnormal sinus node function. Dogs subjected to atrial tachypacing at 400 bpm for 7 days showed prolonged sinus node recovery time, which indicates sinus node dysfunction. Ion channel subunit messenger RNA expression was measured in sinus node tissue and showed downregulation by atrial tachycardia of 2 specific types of subunits: Those underlying the funny current, which is known to be particularly important in cardiac pacemaking activity, and an accessory subunit involved in the slow delayed-rectifier K ϩ channel. Patchclamp studies on sinus node cells isolated from control dogs and dogs subjected to atrial tachypacing confirmed the specific downregulation of funny current and slow delayed-rectifier K ϩ current with atrial tachycardia. These alterations were incorporated in a mathematical model of sinus node electrical activity, which suggested that the funny current changes were the principal factor in sinus node suppression by atrial tachycardia. Our results provide insights into the molecular mechanisms underlying clinically significant bradycardic complications of this common and important clinical syndrome. See p 1576.
Pericardial Fat, Intrathoracic Fat, and Measures of Left Ventricular Structure and Function: The Framingham Heart Study
Pericardial fat, or fat that surrounds the heart, may be associated with obesity-related cardiovascular disease. We explored whether the associations of pericardial fat and measures of cardiac structure and function are linked. We measured pericardial fat in participants from the Framingham Heart Study and assessed measures of cardiac structure and function. We found that multiple different measures of fat were associated with cardiac measures of structure and function, but none persisted after accounting for overall body weight and visceral abdominal fat, the most metabolically active fat depot. An important exception was the relation of pericardial fat and left atrial dimension in men. These results suggest that the systemic effects of obesity on cardiac structure and function may outweigh the local pathogenic effects of pericardial fat. See p 1586.
Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community
The endothelium plays a major role in regulating vascular tone by secreting the potent vasodilator nitric oxide, which is synthesized from L-arginine (Arg) by endothelial nitric oxide synthase. Nitric oxide synthase is competitively inhibited by asymmetric dimethylarginine (ADMA), an endogenous compound that is elevated in renal failure, cardiovascular disease, and diabetes mellitus. Higher ADMA and low ratio of Arg to ADMA are markers of endothelial dysfunction. Prospective investigations have highlighted the role of ADMA as a predictor of cardiovascular disease events and death in patients with coronary artery disease, renal failure, and other high-risk conditions. Data are limited regarding the relations of ADMA and Arg/ADMA ratio to cardiovascular disease incidence and death in the general population. We related plasma ADMA, Arg, and the Arg/ADMA ratio to the incidence of cardiovascular disease and death in 3319 participants from the community-based Framingham study cohort who were followed up for 10.9 years. In multivariable models adjusting for established risk factors, ADMA was associated positively with death, whereas the Arg/ADMA ratio was inversely related. We noted effect modification by diabetes status; ADMA was associated with death in individuals without diabetes but not in individuals with diabetes. ADMA and the Arg/ADMA ratio were not associated with cardiovascular disease incidence. Additional studies evaluating a larger sample of individuals (including those with diabetes) and with longer follow-up are warranted to confirm these observations. See p 1592.
Effects of Different Types of Exercise Training Followed by Detraining on Endothelium-Dependent Dilation in Patients With Recent Myocardial Infarction
Physical exercise is a simple, physiological method for improving endothelial function in patients with ischemic heart disease. It is, however, not yet understood whether endothelial function can be March 31, 2009 improved only by classic aerobic exercise or by other types of exercise such as resistance training known to have many physiological benefits (eg, on muscle function). We therefore investigated endothelial function in a population of patients who had recently had a myocardial infarct, comparing 159 patients, divided into 3 groups, who underwent different types of training (aerobic, resistance, and their combination) with a control group of 50 patients who did not follow an exercise training program. Endothelial function was analyzed by measuring flow-mediated dilation. Our data clearly showed that the benefit of training, provided that it was of a certain intensity and duration, on endothelial dysfunction was independent of the type of exercise (aerobic, resistance, or combined). After 4 weeks of training, flow-mediated dilation improved significantly in all 3 trained groups. Although there was also a slight, spontaneous improvement in the control group, presumably related to the time passed since the infarct, the improvements in the trained groups were very substantial. All types of exercise were well tolerated and did not cause any complications in our patients. This is an additional reason, besides the already-mentioned beneficial effects of physical activity, for encouraging patients to carry out several types of physical activity to promote better long-term adherence to exercise programs. See p 1601.
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A Statewide Collaborative Initiative to Improve the Quality of Care for Patients With Acute Myocardial Infarction and Heart Failure
Various organizations continue to strive to improve the quality of medical care in the United States. In Virginia in 2004, 3 organizations, the Virginia Health Quality Center (Virginia's Medicare Quality Improvement Organization), the American College of Cardiology, and the American Heart Association, combined their efforts into a single collaborative initiative with the goal of improving discharge measures for acute myocardial infarction and heart failure. Twenty-nine hospitals participated in the collaborative initiative. Analysis of Medicare data before and after the initiative showed evidence of greater improvement in the participating hospitals. A paired analysis showed that the participating hospitals had greater improvement in a composite total appropriate care measure, which is an all-or-none measure of quality for both heart failure and acute myocardial infarction patients. A generalized linear mixed model examined the full data set while controlling for hospital-level characteristics. This analysis showed that 7 of 10 individual quality measures improved more in the participating hospitals; however, the improvement was dependent on participation in a prior collaborative initiative. Thus, this collaborative initiative led by 3 organizations appeared to have a favorable impact on quality of care. The experience that we describe and our analysis may provide important insights into how quality improvement efforts can be enhanced. See p 1609.
Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial
The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial was a randomized, partially blind, multinational, multicenter study of aspirin, clopidogrel, and warfarin to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. The primary outcome measure (a composite of mortality, nonfatal stroke, and nonfatal myocardial infarction) and mortality-only results did not support our 2 primary hypotheses that anticoagulation with warfarin is superior to antiplatelet therapy with aspirin in preventing major cardiovascular outcomes and that clopidogrel is superior to aspirin in this population. Although the use of warfarin in our population may have resulted in fewer strokes, this benefit may be offset by increased risk from bleeding. Physicians should balance the increased bleeding risks with decreased stroke risk when considering the use of warfarin. Given the absence of significant differences in the primary end point or survival, this study does not justify a systematic avoidance of aspirin in patients with chronic heart failure in sinus rhythm. See p 1616.
Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Despite the arterial wall stress caused by high blood pressure, patients with essential hypertension are paradoxically more exposed to thrombotic (ie, acute myocardial infarct and ischemic stroke) rather than hemorrhagic complications. It is conceivable that the dysfunctional endothelium, an early vascular alteration in hypertension, and other classic risk factors might be the promoter of the increased atherothrombotic risk. In line with this possibility, recent findings suggest that in addition to the regulation of vascular tone, abnormal endothelium-derived regulation of endogenous fibrinolysis could account for the atherothrombotic complications that characterize essential hypertension. Accordingly, the release of tissue plasminogen activator (tPA) has been proposed recently as a new and distinct marker of endothelial function in humans. The results of the present study show that in healthy conditions, the release of tPA induced by the endothelial agonist bradykinin depends on the activation of both NO and NO-independent pathways. In hypertensive patients, tPA release is reduced because of the impaired NO availability, whereas the residual tPA release is only sustained by NO-independent mechanisms. Interestingly, NO-independent, bradykinin-induced tPA release can be blocked by sulfaphenazole, a compound that in vitro blocks the activity of cytochrome P450 epoxygenase (CYP 2C9), a well-documented source of hyperpolarizing factor. Thus, the possibility exists that in hypertensive patients, the reduced dynamic tPA release from vascular endothelium could be part of a generalized endothelial dysfunction. This alteration may contribute to the hypofibrinolytic state that characterizes this clinical condition and possibly represents a more specific therapeutic target to improve endothelial fibrinolytic function and reduce cardiovascular risk in essential hypertension. See p 1625.
Safety of Short-Term Discontinuation of Antiplatelet Therapy in Patients With Drug-Eluting Stents
We identified 161 cases of late stent thrombosis or very late stent thrombosis from 84 articles in a systematic Medline search. Patients had a mean age of 58.4Ϯ13.4 years, and 88% were male. A total of 19 cases occurred in patients who were receiving dual antiplatelet therapy at the time of the event. If patients stopped both a thienopyridine and acetylsalicylic acid simultaneously, the median time to event was 7 days. If patients had previously stopped a thienopyridine with no ill effect and subsequently stopped acetylsalicylic acid, the median time to event was also 7 days. If a thienopyridine was stopped but acetylsalicylic acid was maintained, the median time to event was 122 days. Among the 48 patients who stopped both agents, 36 cases (75%) occurred within 10 days. Among the 94 patients who stopped a thienopyridine but not acetylsalicylic acid, only 6 cases (6%) occurred within 10 days. If acetylsalicylic acid therapy is maintained, short-term discontinuation of a thienopyridine may be relatively safe in patients with drug-eluting stents. See p 1634.
